Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.

The expression of epidermal growth factor receptor (EGFR) was studied immunohistochemically in 234 cases of transitional cell bladder cancer. EGFR was overexpressed in 35% of cases and distinct nuclear localisation of EGFR positivity was found in 31% of the tumours. Overexpression was related to invasive growth, grade 2-3 histology, non-papillary type, DNA aneuploidy and high proliferation rate of cancer cells. The expressions of p53 and EGFR were interrelated, while expression of c-erbB-2 was independent of EGFR expression. Progression of superficial tumours, recurrence-free survival and survival were independently related to overexpression of EGFR in multivariate analysis. T category, S-phase fraction and non-papillary type included all the available prognostic information when the entire cohort was analysed by multivariate methods. The results show that overexpression of EGFR is related to several malignant features and prognosis in superficial bladder cancer. Moreover, the results suggest that overexpression of EGFR is usually a late event in bladder cancer development related to genetic instability rather than an early event in malignant transformation. Further studies are still needed to establish whether the direct measurement of cell proliferation or analysis of growth factor receptors and other oncoproteins gives more accurate prognostic information in bladder cancer.

• Publication year

  1994

• Venue

  British Journal of Cancer

• Publication date

  1994-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/bjc.1994.220PMID 7911031PMCID 1969432
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunohistochemical distribution patterns of epidermal growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium

  2005cited by this paper
• Localization of human epidermal growth factor receptor in cervical intraepithelial neoplasias

  2004cited by this paper
• Epidermal‐growth‐factor‐receptor expression is associated with rapid tumor proliferation in bladder cancer

  1994cited by this paper
• Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.

  1993cited by this paper
• Proliferative activity of urothelial neoplasms: comparison of BrdU incorporation, Ki67 expression, and nucleolar organiser regions.

  1993cited by this paper
• Effects of EGF, BFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain‐tumour biopsies In Vitro

  1993cited by this paper
• Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer.

  1993cited by this paper
• In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high s‐phase index

  1993cited by this paper
• Over‐expression of p53 nuclear oncoprotein in transitional‐cell bladder cancer and its prognostic value

  1993cited by this paper
• Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional‐cell bladder cancer

  1993cited by this paper
• Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

  1993influential reference
• c-erbB-2, a Tyrosine Kinase Growth Factor Receptor and its Role in Breast Cancer

  1992cited by this paper
• Epidermal growth factor and transforming growth factor alpha stimulate or inhibit proliferation of a human renal adenocarcinoma cell line depending on cell status: differentiation of the two pathways by G protein involvement.

  1992cited by this paper
• Suppression of gene amplification in human cell hybrids.

  1992cited by this paper
• Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer.

  1992cited by this paper
• Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.

  1992cited by this paper
• Histological and quantitative prognostic factors in transitional cell bladder cancer treated by cystectomy.

  1992cited by this paper
• Independent clinical, histological and quantitative prognostic factors in transitional‐cell bladder tumours, with special reference to mitotic frequency

  1992cited by this paper
• Immunohistochemical detection of the epidermal growth factor receptor in paraffin‐embedded human tissues

  1991cited by this paper
• Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder.

  1991cited by this paper
• Expression of c-erbB-2 gene product in urinary bladder cancer.

  1991cited by this paper
• Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer

  1991cited by this paper
• Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.

  1991cited by this paper
• The epidermal growth factor receptor and the prognosis of bladder cancer

  1990cited by this paper
• Nucleocytoplasmic transport is enhanced concomitant with nuclear accumulation of epidermal growth factor (EGF) binding activity in both 3T3-1 and EGF receptor reconstituted NR-6 fibroblasts

  1990cited by this paper
• Immunohistochemical Analysis of c‐erbB‐2 Oncogene Product and Epidermal Growth Factor Receptor Expression in Human Urinary Bladder Carcinomas

  1990cited by this paper
• TNM Classification of Malignant Tumours

  1987cited by this paper
• Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor

  1986cited by this paper
• Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors.

  1986cited by this paper
• Clinical practice in urology: Bladder cancer. E. J. Zingg and D. M. A. Wallace. 249 × 170 mm. Pp.301 + xii. Illustrated. 1985. Wimbledon: Springer-Verlag. £45

  1986cited by this paper
• The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

  1985cited by this paper
• Monoclonal antibodies against the human epidermal growth factor receptor from A431 cells. Isolation, characterization, and use in the purification of active epidermal growth factor receptor.

  1984cited by this paper
• Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptors in human placenta membranes and A431 cells.

  1983cited by this paper
• Alfred P. Sloan Jr. Award. The epidermal growth factor (EGF)

  1983cited by this paper
• Epidermal growth factor receptors

  1981cited by this paper
• Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.

  1980cited by this paper
• Terminal differentiation of cultured human epidermal cells.

  1977cited by this paper
• Regression models and life tables (with discussion

  1972cited by this paper
• A computer program for comparing K samples with right-censored data.

  1972cited by this paper
• transitional cell carcinoma

  year unknowncited by this paper

• Development and landscape of maintenance therapy after first-line treatment of advanced or metastatic urothelial carcinoma

  2025cites this paper
• Nuclear Epidermal Growth Factor Receptor Overexpression as a Survival Predictor in Oral Squamous Cell Carcinoma

  2023cites this paper
• Significance of nuclear EGFR and ABCG2 expression in malignant transformation of oral potentially malignant disorders

  2022cites this paper
• Prognostic Impact of Membranous/Nuclear Epidermal Growth Factor Receptor Localization in Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Transferrin-Conjugated Polymer-Coated Mesoporous Silica Nanoparticles Loaded with Gemcitabine for Killing Pancreatic Cancer Cells

  2020cites this paper
• Role of tyrosine kinases in bladder cancer progression: an overview

  2020cites this paper
• Mutations in gliclazide‐associated genes may predict poor bladder cancer prognosis

  2019cites this paper
• Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression

  2019cites this paper
• Chapter 35 – Personalized Medicine

  2018cites this paper
• Risk Factors and Molecular Features Associated with Bladder Cancer Development

  2018cites this paper
• NFkB hyperactivation causes invasion of esophageal squamous cell carcinoma with EGFR overexpression and p120-catenin down-regulation

  2018cites this paper
• [Nuclear EGFR: a new mode of oncogenic signalling in cancer].

  2018cites this paper
• Molecular Prognostication in Bladder Cancer.

  2018cites this paper
• Correlation of epidermal growth factor receptor score with prognostic variables in transitional cell carcinoma of urinary bladder among north-eastern Indian population

  2018cites this paper
• Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody

  2018cites this paper
• Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications

  2018influential citation
• 2 Molecular Pathways of Bladder Cancer Development and Progression

  2018cites this paper
• Epidermal growth factor receptor function in the human urothelium

  2018cites this paper
• EGFR family inhibition identifies p 38 MAPK as a potential therapeutic target in bladder cancer

  2017cites this paper
• Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.

  2017cites this paper
• Site-specific conjugation of single domain antibodies to liposomes enhances photosensitizer uptake and photodynamic therapy efficacy.

  2016cites this paper
• Involvement of cysteine‐rich protein 61 in the epidermal growth factor‐induced migration of human anaplastic thyroid cancer cells

  2016cites this paper
• Regulation of transforming growth factor beta (TGFβ) at the level of nuclear entry

  2016cites this paper
• Evaluating the Prevalence of the Epidermal Growth Factor Receptor in Transitional Cell Carcinoma of Bladder and its Relationship With Other Prognostic Factors

  2016cites this paper
• Molecular substratification of bladder cancer: moving towards individualized patient management

  2016cites this paper
• Epidermal Growth Factor Receptor and Ki-67 as Predictive Biomarkers Identify Patients Who Will Be More Sensitive to Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Radical Nephroureterectomy

  2016cites this paper
• New Agents for the Treatment of Advanced Bladder Cancer.

  2016cites this paper
• p120-catenin down-regulation and epidermal growth factor receptor overexpression results in a transformed epithelium that mimics esophageal squamous cell carcinoma.

  2015cites this paper
• Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years

  2015cites this paper
• Nuclear Functions of Receptor Tyrosine Kinases

  2015cites this paper
• Nuclear EGFR characterize still controlled proliferation retained in better differentiated clear cell RCC.

  2015cites this paper
• The Nucleus-Localized Epidermal Growth Factor Receptor Is SUMOylated.

  2015cites this paper
• Cdc42 induces EGF receptor protein accumulation and promotes EGF receptor nuclear transport and cellular transformation

  2015cites this paper
• Enhancing photodynamic therapy of refractory solid cancers : Combining second-generation photosensitizers with multi-targeted liposomal delivery

  2015cites this paper
• Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer.

  2015cites this paper
• Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease

  2015cites this paper
• The route to personalized medicine in bladder cancer: where do we stand?

  2015cites this paper
• Combined Treatment with Troglitazone and Lovastatin Inhibited Epidermal Growth Factor-Induced Migration through the Downregulation of Cysteine-Rich Protein 61 in Human Anaplastic Thyroid Cancer Cells

  2015cites this paper
• DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer

  2015cites this paper
• Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases

  2015cites this paper
• Molecular Biology of Urothelial Cancer

  2015cites this paper
• Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM

  2015cites this paper
• The role of LMTK 3 in chromatin remodeling and transcriptional regulation

  2015cites this paper
• Invasive Bladder Cancer: Combined Modality Treatment

  2015cites this paper
• Organization of microtubule assemblies in Dictyostelium syncytia depends on the microtubule crosslinker, Ase1

  2015cites this paper
• Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway

  2015cites this paper
• Second-line therapies in metastatic urothelial carcinoma.

  2015cites this paper
• Epidermal growth factor receptor expression in canine transitional cell carcinoma

  2014cites this paper
• Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives

  2014cites this paper
• Words of wisdom. Re: Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.

  2014cites this paper
• Activation of EGFR Signaling from Pilocytic Astrocytomas to Glioblastomas

  2014cites this paper
• Biomarkers in bladder cancer: translational and clinical implications.

  2014cites this paper
• A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

  2014cites this paper
• Disturbed Tumor Necrosis Factor System is Linked with Lower eGFR and Chronic Inflammation in Hypertension

  2014cites this paper
• Predictive markers in bladder cancer: Do we have molecular markers ready for clinical use?

  2014cites this paper
• MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer

  2013cites this paper
• Nkd2, a negative regulator of Wnt pathway, delays mitotic exit in Hela cell

  2013cites this paper
• Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation.

  2013cites this paper
• Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder.

  2012cites this paper
• Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder

  2012cites this paper
• Molecular Pathogenesis of Bladder Cancer

  2012cites this paper
• Targeted agents in second-line bladder cancer therapy

  2012cites this paper
• Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

  2012cites this paper
• Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer.

  2012cites this paper
• Follow-up procedures for non-muscle-invasive bladder cancer: an update

  2012cites this paper
• Selective organ preservation in muscle-invasive bladder cancer: review of the literature.

  2012cites this paper
• Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.

  2012cites this paper
• Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis

  2012cites this paper
• P16, c-erbB2 and Ki67 immunoexpression in urothelial carcinomas of the bladder.

  2011cites this paper
• Mesane Kanseri Gelişiminde Moleküler Mekanizmaların Rolü

  2011cites this paper
• The nuclear epidermal growth factor receptor signaling network and its role in cancer.

  2011influential citation
• Expression of NRG1 and its receptors in human bladder cancer

  2011cites this paper
• Urothelial carcinomas: a focus on human epidermal receptors signaling.

  2011cites this paper
• Expression and function role of DNA methyltransferase 1 in human bladder cancer

  2011cites this paper
• Epidermal Growth Factor Receptor-Targeted Therapies

  2011cites this paper
• Correlation of HER-2/neu Oncogene Expression And Grades of Transitional Cell Carcinoma of Bladder

  2011cites this paper
• Assessment of Phytochemicals in Preventing Oxidatively Damaged DNA in Bladder Cancer

  2011cites this paper
• Contribution of Ectodomain Mutations in Epidermal Growth Factor Receptor to Signaling in Glioblastoma Multiforme

  2011cites this paper
• The Impact of Chemoprevention on Treatment Regimens for Non- Muscle Invasive Bladder Cancer

  2011cites this paper
• Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.

  2011cites this paper
• Prognostic Markers for Bladder Cancer

  2011cites this paper
• Current and Emerging Strategies for the Management of Bladder Cancer

  2011cites this paper
• Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer?

  2011cites this paper
• Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine suppresseur de tumeur p14ARF dans les adénocarcinomes pulmonaires

  2011cites this paper
• Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine

  2011cites this paper
• Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654

  2010cites this paper
• Carcinogenetic Pathway of Superficial Low-Grade Urothelial Carcinoma

  2010cites this paper
• Transitional research in bladder cancer: From molecular pathogenesis to useful tissue biomarkers

  2010cites this paper
• A Role For Lipid Rafts In Egfr Tki Resistance In Breast Cancer

  2010cites this paper
• Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects

  2009cites this paper
• A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

  2009cites this paper
• Aberrant EGFR Signaling in Glioma

  2009cites this paper
• Effect of Vascular Endothelial Growth Factor and Its Receptor Inhibitor on Proliferation and Invasion in Bladder Cancer

  2009cites this paper
• Conservative treatment of invasive bladder cancer

  2009cites this paper
• Differential effects of MAPKs signaling on the growth of invasive bladder cancer cells.

  2009cites this paper
• Ultraviolet irradiation‐induces epidermal growth factor receptor (EGFR) nuclear translocation in human keratinocytes

  2009cites this paper
• Strategies to improve drug delivery in bladder cancer therapy

  2009cites this paper
• Molecular pathogenesis and diagnostics of bladder cancer.

  2009cites this paper
• Total Cystectomy Versus Bladder Preservation Therapy for Locally Invasive Bladder Cancer: Effect of Combined Therapy Using Balloon-Occluded Arterial Infusion of Anticancer Agent and Hemodialysis With Concurrent Radiation

  2009cites this paper
• Epidermal growth factor promotes epidermal growth factor receptor nuclear accumulation by a pathway dependent on cytoskeleton integrity in human breast cancer cells.

  2009cites this paper